Group 1 - The company, HuaLing Pharmaceutical, has released a positive profit forecast, reporting a profit of approximately RMB 1.184 billion for the current reporting period [1] - Following the termination of the exclusive promotion service agreement with Bayer on January 1, 2025, the company has recognized RMB 1.244 billion of unamortized contract liabilities as income, contributing to the revenue for the group [1] - The successful transfer of the commercialization task for Huatangning® in mainland China and improvements in production efficiency have led to an increase in gross profit margin [1] Group 2 - In the first half of the year, the company sold approximately 1,764,000 boxes of Huatangning®, generating net sales of about RMB 217 million, compared to 846,000 boxes and RMB 103 million in net sales during the same period in 2024, reflecting a sales increase of 111.8% [1] - The expected gross profit for the six months ending June 30, 2025, is approximately RMB 118 million, a significant increase from RMB 47.8 million in the same period in 2024 [2] - The gross profit margin is projected to rise from 46.5% in 2024 to about 54.2% for the six months ending June 30, 2025, primarily due to improved production efficiency and reduced unit production costs [2]

Group 1 - The company expects a profit of approximately 1.184 billion RMB for the six months ending June 30, 2025, driven by improved commercialization efficiency and sales growth [1][2] - The termination of the exclusive promotion service agreement with Bayer on January 1, 2025, allowed the company to recognize previously unamortized contract liabilities of 1.244 billion RMB as revenue, contributing to profit [1] - The successful transfer of commercialization tasks for Huadongning® in China and improvements in production efficiency have led to an increase in gross profit margin [1][2] Group 2 - The company sold approximately 1.764 million boxes of Huadongning® with net sales of about 217 million RMB for the six months ending June 30, 2025, reflecting a 111.8% increase in sales compared to 846,000 boxes and 103 million RMB in the same period of 2024 [1] - The expected gross profit for the six months ending June 30, 2025, is about 118 million RMB, significantly up from 47.8 million RMB in 2024, with the gross margin increasing from 46.5% to approximately 54.2% [2] - The transition from loss to substantial profit in the first half of 2025 indicates the successful implementation of the company's commercialization strategy, enhancing market confidence [2]

Company News - China Railway Construction (01186.HK) reported a new contract amount of approximately 1,056.17 billion yuan for the first half of the year, a year-on-year decrease of 4.04% [2] - China Metallurgical Group (01618.HK) announced a new contract amount of 548.2 billion yuan for the first half of the year, down 19.1% year-on-year [2] - Sichuan Chengyu Expressway (00107.HK) won the bid for the G5 Jingkun Expressway Chengdu to Ya'an section expansion project, with a total investment of approximately 28.548 billion yuan [2] - Road King Infrastructure (01098.HK) reported total property sales of 5.232 billion yuan for the first half of the year, a decrease of 28.37% year-on-year [2] - Amax Holdings (00880.HK) plans to acquire a property in Hengqin for 724.2 million yuan to diversify its business portfolio [2] - Chaoyue Eye Hospital (02219.HK) signed a construction contract for the first phase of its comprehensive medical facility project, with a contract value of 223 million yuan [2] - Bay Area Development (00737.HK) reported total toll revenue of 243 million yuan for June, a year-on-year decrease of 4% [2] - Decent Pharmaceuticals-B (06996.HK) received approval for its drug, Hivio®, for the second-line treatment of multiple myeloma in China [2] - Tianchen Holdings (01201.HK) plans to invest 30 million yuan to establish a joint venture in Shenzhen for new energy heavy truck charging stations [2] Performance Summary - WuXi AppTec (02359.HK) reported mid-year revenue of 20.799 billion yuan, a year-on-year increase of 20.64%, and a net profit of 8.561 billion yuan, up 101.92% year-on-year [3] Earnings Announcements - China Nonferrous Mining (01258.HK) issued a profit warning, expecting mid-term net profit of approximately 258 million USD, a year-on-year increase of about 18% [4] - Hualing Pharmaceutical-B (02552.HK) issued a profit warning, expecting mid-term net profit of approximately 1.184 billion yuan, turning from loss to profit [4] - Little Yellow Duck (02250.HK) issued a profit warning, expecting mid-term revenue to increase by over 30% year-on-year [4] - Qingci Games (06633.HK) issued a profit warning, expecting mid-term net profit to increase by approximately 78%-130% year-on-year [4] - Goodbaby International (01086.HK) issued a profit warning, expecting mid-term net profit to decrease by approximately 40%-50% year-on-year [4] - Qianhai Health (00911.HK) issued a profit warning, expecting mid-term net profit to decrease by approximately 60%-70% year-on-year [4] - Tianan Health (00383.HK) issued a profit warning, expecting mid-term net profit to decrease to approximately 7 million to 17 million HKD [4] - Pacific Network (00543.HK) issued a profit warning, expecting mid-term net loss of approximately 5 million to 15 million yuan [4] Buyback and Increase Dynamics - HSBC Holdings (00005.HK) repurchased 348,700 shares for approximately 35.487 million HKD at a price of 101.4-102 HKD [3] - China Eastern Airlines (00670.HK) repurchased 2.5 million shares for approximately 7.4983 million HKD at a price of 2.97-3.03 HKD [3] - Founder Holdings (00418.HK) canceled a total of 17.9962 million shares that had been repurchased [3]

Core Viewpoint - The company anticipates a significant turnaround in profitability, projecting a profit of approximately RMB 1,184.1 million for the six months ending June 30, 2025, compared to a loss of about RMB 142.0 million in the same period of 2024 [1][2] Group 1: Financial Performance - The expected profit increase is attributed to the successful transfer of commercialization tasks for Huadongning in China and improvements in production efficiency, leading to a higher gross margin [2] - For the six months ending June 30, 2025, the company sold approximately 1,764,000 boxes of Huadongning, generating a net sales revenue of about RMB 217.4 million, compared to 846,000 boxes and RMB 102.7 million in the same period of 2024, reflecting a sales growth of 111.8% [2] - The anticipated gross profit for the six months ending June 30, 2025, is approximately RMB 117.8 million, a significant increase from RMB 47.8 million in 2024, driven by increased sales and improved gross margin [2] Group 2: Operational Changes - The company has fully taken over the commercialization tasks for Huadongning in mainland China and has appointed a sales leader with over 20 years of experience in diabetes drug commercialization to lead its sales and marketing efforts [1] - The gross margin is expected to rise from 46.5% in 2024 to approximately 54.2% for the six months ending June 30, 2025, primarily due to enhanced production efficiency and increased output, resulting in lower unit production costs [2]

（於開曼群島註冊成立的有限公司） （股份代號：2552） 正面盈利預告 本公告乃由華領醫藥（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯合交 易所有限公司證券上市規則第13.09條及香港法例第571章證券及期貨條例第XIVA 部之內幕消息條文而作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 HUA MEDICINE 華領醫藥 1 本公司仍在確定本集團於本報告期的中期業績，而本公告所載資料為基於本集團 管理賬目的初步統計數字及初步評估，未經本公司核數師審核或審閱。股東及潛 在投資者務請參閱將於2025年8月公佈的本報告期本公司中期業績公告。 承董事會命 行政總裁兼執行董事 陳力博士 香港，2025年7月28日 於本公告日期，董事會成員包括執行董事陳力博士、林潔誠先生及 張怡博士；非執行董事Robert Taylor Nelsen先生；以及獨立非執行董事 William Robert Keller先生、徐耀華先生及張耀樑先生。 2 本公司董 ...

Summary of Key Points Core Viewpoint - As of July 14, a total of 138 stocks reached their 52-week highs, indicating a strong performance in the market, with notable leaders including Green Heart Group Holdings, OK Blockchain, and Pearl River Steel Pipe [1]. Group 1: Top Performers - Green Heart Group Holdings (02999) achieved a closing price of 0.013 with a peak of 0.017, marking a 70.00% increase [1]. - OK Blockchain (01499) closed at 0.680, reaching a high of 0.690, reflecting a 48.39% rise [1]. - Pearl River Steel Pipe (01938) had a closing price of 0.335 and a peak of 0.340, resulting in a 33.33% increase [1]. Group 2: Other Notable Stocks - Weishi Jiajie (00856) saw a 32.01% increase, closing at 8.870 with a high of 11.300 [1]. - Cloud Intelligence (09678) reached a high of 520.000, closing at 510.000, which is a 20.99% increase [1]. - China Chengtong Development Group (00217) closed at 0.165 with a peak of 0.166, marking a 14.48% rise [1]. Group 3: Additional Stocks with Significant Increases - Sihuan Pharmaceutical (00460) closed at 1.380, reaching a high of 1.430, which is a 14.40% increase [1]. - Taited Pharmaceutical (03880) had a closing price of 36.950 and a peak of 37.400, reflecting a 13.85% rise [1]. - Beihai Kangcheng-B (01228) closed at 0.850 with a high of 0.960, resulting in a 12.94% increase [1].

Company Overview - Hualing Pharmaceutical-B is an innovative drug research and commercialization company based in Shanghai, China, with operations in the US and Hong Kong [3] - The company focuses on unmet medical needs and aims to develop new therapies for global patients, particularly in diabetes care [3] - Hualing Pharmaceutical's core product, Huatangning (Dorzagliatin), targets glucose sensors and aims to improve glucose sensitivity in type 2 diabetes patients [3] Financial Performance - As of December 31, 2024, Hualing Pharmaceutical-B reported total revenue of 256 million yuan, a year-on-year increase of 234.02% [2] - The company recorded a net profit attributable to shareholders of -250 million yuan, a decrease of 18.42% year-on-year [2] - The gross profit margin stood at 48.74%, while the debt-to-asset ratio was 108.87% [2] Stock Performance - Over the past month, Hualing Pharmaceutical-B has seen a cumulative increase of 0.3%, while its year-to-date increase is 125.34%, outperforming the Hang Seng Index by 20.34% [2] - The stock closed at 3.64 HKD per share, with a trading volume of 15.81 million shares and a turnover of 56.15 million HKD, reflecting a volatility of 11.85% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 2.93 times, with a median of 6.71 times [2] - Hualing Pharmaceutical-B has a P/E ratio of -12.86 times, ranking 117th in the industry [2] - Comparatively, other companies in the sector have P/E ratios such as 0.85 times for Qianyou Pharmaceutical, 1.42 times for Kingsray Biotechnology, and 3.1 times for Dongrui Pharmaceutical [2] Product Development and Market Strategy - Huatangning received approval from the National Medical Products Administration (NMPA) in China on September 30, 2022, for use in treating adult type 2 diabetes [3] - The drug is designed to be effective for patients with varying degrees of renal impairment without the need for dosage adjustment [3] - Hualing Pharmaceutical plans to collaborate with Bayer to promote the commercialization of Huatangning in China [3] - The company aims to explore the potential of Dorzagliatin in diabetes remission, with a 52-week remission rate of 65.2% observed in clinical trials [3]

Dorzagliatin Overview - Dorzagliatin is a first-in-class drug with global rights, targeting the underlying cause of Type 2 Diabetes (T2D) by addressing impaired glucose homeostasis[13] - As of December 31, 2019, Hua Medicine had RMB 1.1 billion in cash[13] - The global T2D population is 453 million, with 120 million in China alone, representing a massive market opportunity[13] Clinical Trial Results - In a Phase III monotherapy trial, dorzagliatin achieved the primary endpoint, demonstrating a significant and sustainable reduction in HbA1c safely[13] - In the HMM0301 Phase III trial, the dorzagliatin-treated group showed a 1.07% HbA1c reduction from a baseline of 8.35%, compared to a 0.5% reduction from a baseline of 8.37% in the placebo group (p < 0.0001)[62] - 45.4% of patients treated with dorzagliatin achieved a target HbA1c level of 7.0% or less at 24 weeks, compared to 21.5% of patients treated with placebo (p < 0.0001)[62] - Patients treated with dorzagliatin achieved a homeostasis control rate of 45.0% compared with 21.5% in the placebo group (p < 0.0001)[62] Combination Therapy - A Phase I trial (HMM0111) showed that dorzagliatin combined with sitagliptin (DPP-4 inhibitor) resulted in a 33% reduction (p<0.01) in postprandial glucose level AUEC (0-4hr)[74] - A Phase I trial (HMM0112) showed that dorzagliatin combined with empagliflozin (SGLT-2 inhibitor) resulted in a 38% reduction (p<0.0001) in postprandial glucose level AUEC (0-4hr)[79] China Market - China has the largest diabetes population globally, with approximately 125 million T2D patients[232] - The diagnosis rate in China was 50.4% in 2018 and is expected to rise to 82.2% in 2028[235] - The China anti-diabetics market is projected to grow from RMB 57.3 billion in 2018 to RMB 135.6 billion in 2025, with an expected CAGR of 11.7% from 2018 to 2028[246]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 華領醫藥 （於開曼群島註冊成立的有限公司） HUA MEDICINE （股份代號：2552） 2025年6月26日舉行的股東週年大會的投票表決結果 謹此提述華領醫藥（「本公司」）日期均為2025年4月24日的通函（「通函」）及本公司 股東週年大會（「股東週年大會」）通告。除另有界定外，本公告所用詞彙與通函所 界定者具有相同涵義。 於2025年6月26日舉行的本公司股東週年大會上，所有列載於日期為2025年4月 24日的股東週年大會通告內提呈的決議案均以投票方式進行表決。投票表決結果 如下： | | 普通決議案 | 票數(%) | | | --- | --- | --- | --- | | | | 贊成 | 反對 | | 1. | 省覽本公司截至2024年12月31日止年度經 | 12,804,099 | 0 | | | 審核綜合財務報表及董事會報告與核數師報 | (100.00%) | (0.00%) | ...

HUA MEDICINE 華領醫藥 （於開曼群島註冊成立的有限公司） （股份代號：2552） 董事名單與其角色和職能 自2025年6月25日起，華領醫藥董事會（「董事會」）成員載列如下： 執行董事 C 有關董事委員會主席 M 有關董事委員會成員 非執行董事 Robert Taylor NELSEN先生 獨立非執行董事 William Robert KELLER先生 徐耀華先生 張耀樑先生 董事會下設四個委員會。下表載列董事會成員在各委員會中擔任的職位。 | 董事委員會 | 審核 | 薪酬 | 提名 | 戰略 | | --- | --- | --- | --- | --- | | 董事 | 委員會 | 委員會 | 委員會 | 委員會 | | 陳力先生 | – | – | – | C | | 林潔誠先生 | – | – | – | M | | 張怡女士 | – | – | – | – | | Robert Taylor NELSEN先生 | – | – | C | M | | William Robert KELLER先生 | M | C | M | – | | 徐耀華先生 | M | M | M | – | | ...